Literature DB >> 3424863

Plasma protein binding of ceftriaxone.

A C Popick1, W G Crouthamel, I Bekersky.   

Abstract

1. The plasma protein binding characteristics of ceftriaxone, a new cephalosporin antibiotic, were determined in human, baboon, rabbit, dog and rat plasma. 2. The protein binding of ceftriaxone was similar and concentration-dependent in human, baboon, rabbit and rat plasma, being highly bound (90-95%) at low concentrations (less than 100 micrograms/ml) but considerably less bound (approx. 60%) at high concentrations (greater than 400 micrograms/ml). Binding in dog plasma was also concentration-dependent but much lower (approx. 25%) at lower concentrations (30 micrograms/ml) and virtually unbound (2%) at high concentrations (1 mg/ml) over a similar concentration range. 3. Binding of ceftriaxone to human plasma involved two sites: a high affinity-low capacity (saturable) site and a low affinity-high capacity site. Binding to dog plasma apparently was at a single, high affinity-low capacity site. 4. The pharmacokinetics of ceftriaxone in an animal species with binding characteristics similar to man (baboon), appear to be non-linear when based on total drug concentration and linear when based on the free drug concentration. In the dog, pharmacokinetic parameters did not change appreciably if calculated from total or free drug concentrations, due to the low protein binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3424863     DOI: 10.3109/00498258709167406

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  19 in total

1.  Effect of protein binding on the pharmacological activity of highly bound antibiotics.

Authors:  Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

2.  Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model.

Authors:  Jayesh A Dhanani; Benjamin Ahern; Liad Lupinsky; Karen Jackson; Steven C Wallis; Mohd H Abdul-Aziz; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Pharmacokinetics of ertapenem in healthy young volunteers.

Authors:  A K Majumdar; D G Musson; K L Birk; C J Kitchen; S Holland; J McCrea; G Mistry; M Hesney; L Xi; S X Li; R Haesen; R A Blum; R L Lins; H Greenberg; S Waldman; P Deutsch; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Influence of assay methodology on the measurement of free serum ceftriaxone concentrations.

Authors:  S J Kohlhepp; D N Gilbert; J E Leggett
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia.

Authors:  Martha J Gentry-Nielsen; Keith M Olsen; Laurel C Preheim
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

7.  Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.

Authors:  Michael Schleibinger; Cathérine L Steinbach; Christoph Töpper; Alexander Kratzer; Uwe Liebchen; Frieder Kees; Bernd Salzberger; Martin G Kees
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

8.  Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Authors:  Yanli Zhao; Merit E Cudkowicz; Jeremy M Shefner; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jerold S Harmatz; David Schoenfeld; David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2014-05-16       Impact factor: 3.126

9.  Pharmacokinetics of ceftriaxone in liver-transplant recipients.

Authors:  A Toth; H Y Abdallah; R Venkataramanan; L Teperman; G Halsf; M Rabinovitch; G J Burckart; T E Starzl
Journal:  J Clin Pharmacol       Date:  1991-08       Impact factor: 3.126

10.  Pharmacokinetics and protein binding of ceftriaxone during pregnancy.

Authors:  P Bourget; H Fernandez; V Quinquis; C Delouis
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.